Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALOGLIPTIN vs JANUMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alogliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it increases the levels of active incretin hormones (GLP-1 and GIP), which stimulate insulin secretion in a glucose-dependent manner and suppress glucagon release, thereby improving glycemic control.
Janumet is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases incretin levels (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus,Combination therapy with metformin, sulfonylurea, thiazolidinedione, or insulin
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
25 mg orally once daily
Initial dose: 50 mg sitagliptin/500 mg metformin hydrochloride twice daily orally with meals. Dose may be increased up to 50 mg sitagliptin/1000 mg metformin twice daily based on glycemic response and tolerability.
Terminal elimination half-life is approximately 12-21 hours. This supports once-daily dosing. In patients with renal impairment, half-life is prolonged (e.g., up to 32 hours in severe impairment), necessitating dose adjustment.
Sitagliptin: 12.4 hours (terminal). Clinical context: supports once-daily dosing, but half-life increases in renal impairment. Metformin: 6.2 hours (terminal). Shorter half-life requires multiple daily dosing; prolonged in renal impairment.
Alogliptin is minimally metabolized; approximately 60-70% excreted unchanged in urine. Metabolism involves hepatic microsomal enzymes, primarily CYP2D6 and CYP3A4, but to a minor extent.
Sitagliptin is primarily excreted unchanged in urine via active tubular secretion, with minor metabolism via CYP3A4 and CYP2C8. Metformin is not metabolized and is excreted unchanged in urine by tubular secretion.
Approximately 60-71% of the dose is excreted unchanged in urine via active renal tubular secretion, with about 20% eliminated as metabolites (primarily N-demethylated and N-acetylated derivatives) in urine, and less than 2% in feces. Renal excretion is the major route.
Sitagliptin: 87% renal (unchanged), 13% fecal (metabolites). Metformin: 90-100% renal (unchanged), <5% fecal.
20% bound to plasma proteins, primarily albumin. Binding is concentration-independent.
Sitagliptin: 38% (albumin). Metformin: negligible (<5%).
Volume of distribution is approximately 33 L (0.47 L/kg assuming 70 kg). This suggests distribution into total body water, but not extensive tissue binding.
Sitagliptin: 198 L (≈2.8 L/kg for 70 kg). Metformin: 654 L (≈9.3 L/kg for 70 kg). Clinical meaning: Metformin Vd indicates extensive tissue distribution, predominantly in gastrointestinal tissues and red blood cells.
Oral bioavailability is approximately 100%, indicating complete absorption with minimal first-pass metabolism.
Sitagliptin: 87% (oral). Metformin: 50-60% (oral), variable with food.
e GFR 30-59 m L/min: 12.5 mg orally once daily; e GFR 15-29 m L/min: 6.25 mg orally once daily; e GFR <15 m L/min or dialysis: 6.25 mg orally once daily
Contraindicated if e GFR <30 m L/min/1.73 m2. e GFR 30-45: do not initiate; if already on therapy, reduce dose to 25 mg sitagliptin/500 mg metformin once daily. e GFR 45-60: maximum dose 50 mg sitagliptin/1000 mg metformin twice daily. Monitor renal function.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A and B); not recommended for severe hepatic impairment (Child-Pugh C)
Contraindicated in patients with hepatic impairment (Child-Pugh class A, B, or C) due to metformin component risk of lactic acidosis.
Safety and efficacy not established; no recommended dosing available
Not approved for use in pediatric patients (<18 years). Safety and efficacy not established.
No dose adjustment recommended based on age alone; monitor renal function and adjust dose accordingly
Use with caution; monitor renal function closely. Initiate at lowest dose (25 mg sitagliptin/500 mg metformin) and titrate slowly. Avoid in patients aged ≥80 years unless normal renal function confirmed.
None.
Lactic acidosis: Metformin hydrochloride can cause lactic acidosis, a rare but serious condition. If suspected, discontinue Janumet and treat promptly.
Pancreatitis: Cases of acute pancreatitis have been reported; discontinue if pancreatitis is suspected.,Hypersensitivity reactions: Including anaphylaxis, angioedema, and severe cutaneous adverse reactions.,Heart failure: Consider risk factors; monitor for signs and symptoms.,Severe and disabling arthralgia has been reported.,Acute renal failure: Not recommended in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²) or end-stage renal disease.,Hypoglycemia when used in combination with insulin or sulfonylureas.
Lactic acidosis risk (sepsis, dehydration, hepatic impairment, alcohol abuse, unstable CHF, radiologic contrast studies),Pancreatitis (discontinue if suspected),Hypoglycemia (especially with sulfonylurea or insulin coadministration),Renal impairment (assess renal function before initiation and periodically; contraindicated if e GFR <30 m L/min/1.73 m²),Vitamin B12 deficiency (monitor levels with long-term metformin use),Hypersensitivity reactions (e.g., anaphylaxis, angioedema, Stevens-Johnson syndrome),Heart failure (monitor for signs; cardiovascular outcome trials showed no increased risk with saxagliptin, but caution with DPP-4 inhibitors)
History of serious hypersensitivity reaction to alogliptin or any excipient,Type 1 diabetes mellitus,Diabetic ketoacidosis
Severe renal impairment (e GFR <30 m L/min/1.73 m²),Acute or chronic metabolic acidosis (including diabetic ketoacidosis),History of serious hypersensitivity reaction to Janumet or its components,Use of iodinated contrast agents with e GFR <60 m L/min/1.73 m² or liver disease, alcohol abuse, or conditions altering renal function
No specific food interactions; can be taken with or without food. Avoid excessive alcohol intake due to potential hypoglycemia risk when used with other agents.
Avoid excessive alcohol intake (increases risk of lactic acidosis). Take with food to minimize gastrointestinal upset. No specific food restrictions; maintain consistent carbohydrate intake for blood glucose control.
Alogliptin is classified as FDA Pregnancy Category B. Animal studies showed no teratogenic effects at exposures up to 100 times the human clinical dose. However, no adequate and well-controlled studies in pregnant women exist. Use only if clearly needed. First trimester risk cannot be ruled out; limited human data.
Janumet (sitagliptin/metformin) is classified as FDA Pregnancy Category B for sitagliptin and Category B for metformin. Animal studies show no evidence of teratogenicity, but there are no adequate well-controlled studies in pregnant women. Risk cannot be ruled out. Metformin crosses the placenta and may cause fetal lactic acidosis in third trimester. Generally, insulin is preferred for gestational diabetes management.
It is unknown if alogliptin is excreted in human breast milk. No M/P ratio available. Due to potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account importance to the mother.
Sitagliptin is excreted in rat milk; unknown in humans. Metformin is excreted into human milk at low levels with an estimated infant dose of 0.18-0.4 mg/kg/day (M/P ratio ~0.35-0.65). Due to potential for hypoglycemia and uncertain long-term effects, breastfeeding is not recommended during Janumet therapy.
No specific dose adjustments recommended; however, pregnancy may alter pharmacokinetics of alogliptin. Avoid use when possible, particularly during the second and third trimesters, due to limited safety data.
Janumet is not recommended during pregnancy. If used, dose adjustments may be necessary due to pregnancy-induced increased renal clearance of metformin; however, no specific guidelines exist. Renal function should be monitored closely to avoid metformin accumulation and lactic acidosis. Typically, insulin therapy is initiated.
Alogliptin is a DPP-4 inhibitor with minimal risk of hypoglycemia when used as monotherapy; dosing adjustments required for renal impairment (creatinine clearance <60 m L/min). Monitor for acute pancreatitis and severe arthralgia. No significant weight loss or gain. Use with caution in patients with history of pancreatitis.
Janumet combines sitagliptin (DPP-4 inhibitor) and metformin (biguanide). Dose adjustment required for renal impairment (e GFR <45 m L/min/1.73 m² contraindicated; <30 for metformin component). Monitor for lactic acidosis (rare but serious) especially in hypoxic states. Discontinue for 48 hours before iodinated contrast imaging with metformin component. Pancreatitis risk: monitor for persistent severe abdominal pain. Not for type 1 diabetes or ketoacidosis.
Take alogliptin with or without food once daily.,Do not skip meals, especially if taking other diabetes medications that cause hypoglycemia.,Contact healthcare provider immediately if you experience persistent severe abdominal pain (sign of pancreatitis).,Report any joint pain that is new or worsening.,Store at room temperature away from moisture and heat.
Take with meals to reduce gastrointestinal side effects.,If you miss a dose, take it with your next meal unless the next dose is due; do not double dose.,Monitor for symptoms of pancreatitis (severe abdominal pain, nausea, vomiting) and report immediately.,Report symptoms of lactic acidosis (muscle pain, weakness, difficulty breathing, drowsiness) especially if you have kidney problems or are over 65.,Avoid alcohol while taking this medication to reduce the risk of lactic acidosis.,Stay hydrated, especially if you are sick (vomiting, diarrhea) or exercising intensely.,Check blood sugar regularly as directed; carry a source of sugar for hypoglycemia.,Tell your doctor if you are pregnant, breastfeeding, or planning surgery.
"The coadministration of alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with chloroquine may lead to increased plasma concentrations of chloroquine. This occurs because alogliptin potentially inhibits CYP2C8 and/or CYP3A4, the cytochrome P450 enzymes responsible for chloroquine metabolism. As a result, patients may be at higher risk for chloroquine-related adverse effects such as cardiac arrhythmias (QT prolongation), retinopathy, and hypoglycemia."
"Sunitinib, a tyrosine kinase inhibitor, may enhance the glucose-lowering effects of alogliptin, a DPP-4 inhibitor, by impairing renal function and potentially reducing the renal clearance of alogliptin, leading to increased exposure and risk of hypoglycemia. This interaction is particularly relevant in patients with pre-existing renal impairment or those receiving high-dose sunitinib. Clinical outcomes include episodes of symptomatic hypoglycemia, which may require dose adjustment of antidiabetic therapy."
"Alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases endogenous incretin levels, enhancing glucose-dependent insulin secretion. Mesalazine, known for its anti-inflammatory effects in inflammatory bowel disease, may independently lower blood glucose via unknown mechanisms. Concurrent use could potentiate hypoglycemic effects, especially in patients with diabetes or impaired glucose regulation, increasing the risk of symptomatic hypoglycemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALOGLIPTIN vs JANUMET, answered by our medical review team.
ALOGLIPTIN is a DPP-4 Inhibitor that works by Alogliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it increases the levels of active incretin hormones (GLP-1 and GIP), which stimulate insulin secretion in a glucose-dependent manner and suppress glucagon release, thereby improving glycemic control.. JANUMET is a DPP-4 Inhibitor/Biguanide Combination that works by Janumet is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases incretin levels (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALOGLIPTIN and JANUMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALOGLIPTIN is: 25 mg orally once daily. The standard adult dose of JANUMET is: Initial dose: 50 mg sitagliptin/500 mg metformin hydrochloride twice daily orally with meals. Dose may be increased up to 50 mg sitagliptin/1000 mg metformin twice daily based on glycemic response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALOGLIPTIN and JANUMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALOGLIPTIN is classified as Category C. Alogliptin is classified as FDA Pregnancy Category B. Animal studies showed no teratogenic effects at exposures up to 100 times the human clinical dose. However, no adequate and we. JANUMET is classified as Category C. Janumet (sitagliptin/metformin) is classified as FDA Pregnancy Category B for sitagliptin and Category B for metformin. Animal studies show no evidence of teratogenicity, but there. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.